Neovascular age-related macular degeneration (nAMD) is the leading cause of irreversible blindness in people â¥ 50 years old in the industrialized world, Recently, the most promising treatment of all forms of nAMD is represented by intravitreal anti-Vascular Endothelial Growth Factor (anti-VEGF) drugs . In fact, two of the most important prospective, randomized, large-scale clinical trials on nAMD treatment with intravitreal anti-VEGF have demonstrated a statistically significant improvement in best-corrected visual acuity (BCVA), Ranibizumab, a recombinant, humanized monoclonal antigenbinding antibody fragment that neutralizes all isoforms of VEGF-A (Lucentis, Genentech, Inc., South San Francisco, CA), was approved in the United States and Europe in 2006 for the treatment of nAMD, BCVA using the Early Treatment Diabetic Retinopathy Study (ETDRS) chart has been considered the gold standard tool in order to assess the visual status in macular disorders and a primary end point to evaluate the functional outcome of new drugs in nAMD. On the other hand, it may not provide a complete functional assessment in nAMD patients, Microperimetry MP1 (Nidek, Padova, Italy) is a relatively new equipment providing an objective and quantitative information about whole macular function in patients with nAMD . Moreover, it is increasingly being recognized as a useful clinical tool in the assessment of various retinal pathologies. In addition, retinal function is assessed by using microperimetry in relation to the fundus, and thus spatial light increment sensitivity can be mapped.Moreover, the auto-tracking system corrects for involuntary eye movements allowing an exact point by point correlation between anatomic abnormalities and retinal sensitivity, even in patients with an unstable fixation, providing new insights into the functional impact of neovascular AMD . These central visual field functions are important in day-to-day activities such as those involving contrast and color sensitivity.
Stefano Lazzeri: Analysis of Functional Dissociations between Best Corrected Visual Acuity and Microperimetric Parameters in Neovascular Age-Related Macular Degeneration Patients Underwent to Three Monthly Ranibizumab Injections
Last date updated on June, 2021